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Ribavirin Inhibits In Vitro Hepatitis E Virus Replication through
Depletion of Cellular GTP Pools and Is Moderately Synergistic with
Alpha Interferon
Yannick Debing,a Suzanne U. Emerson,b Yijin Wang,c Qiuwei Pan,a,c Jan Balzarini,a Kai Dallmeier,a Johan Neytsa
‹Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgiuma; Molecular Hepatitis, Laboratory of Infectious Diseases,
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USAb; Erasmus MC-University Medical Center, Department of
Gastroenterology & Hepatology, Rotterdam, Netherlandsc
Hepatitis E virus (HEV) is a common cause of acute hepatitis that results in highmortality in pregnant women andmay establish
chronic infections in immunocompromised patients. We demonstrate for the first time that alpha interferon (IFN-) and ribavi-
rin inhibit in vitroHEV replication in both a subgenomic replicon and an infectious culture system based on a genotype 3 strain.
IFN- showed a moderate but significant synergism with ribavirin. These findings corroborate the reported clinical effectiveness
of both drugs. In addition, the antiviral activity of ribavirin against wild-type genotype 1, 2, and 3 strains was confirmed by im-
munofluorescence staining. Furthermore, the in vitro activity of ribavirin depends on depletion of intracellular GTP pools,
which is evident from the facts that (i) other GTP-depleting agents (5-ethynyl-1--D-ribofuranosylimidazole-4-carboxamide
[EICAR] andmycophenolic acid) inhibit viral replication, (ii) exogenously added guanosine reverses the antiviral effects, and
(iii) a strong correlation (R2 0.9998) exists between the antiviral activity and GTP depletion of ribavirin and other GTP-deplet-
ing agents.
Hepatitis E virus (HEV) is a positive-sense, single-strandedRNA virus and is classified as the sole member of theHepevi-
rus genus in the Hepeviridae family (1, 2). HEV is usually trans-
mitted feco-orally and may cause self-limiting acute hepatitis. At
least four genotypes are currently recognized: genotypes 1 and 2
seem to infect only humans and are endemic in developing re-
gions, with an estimated 70,000 deaths annually (3), while geno-
types 3 and 4 are zoonotic agents, with domestic pigs as theirmain
reservoir (1, 2). The latter two genotypes cause sporadic autoch-
thonous infections in both developing and industrialized parts of
theworld, e.g., through consumption of undercooked pigmeat (1,
2). In addition, related viruses have been found in several animal
species, including chickens (avian HEV) (4), rats (5), rabbits (6),
ferrets (7), bats (8), and trout (cutthroat trout virus [CTV]) (9).
Infections with HEV are often severe in pregnant women in-
fected with genotype 1, with up to 25%mortality (1, 10). In addi-
tion, genotype 3 can cause chronic infections, particularly in im-
munocompromised individuals (11). The first consideration in
treating chronic hepatitis E, especially in transplant patients, is
lowering immunosuppressive therapy, which induces clearance in
over 30% of cases (12). An additional course of pegylated alpha
interferon (IFN-) for 3 months or longer proved successful in
most cases described (13), but ribavirin (RBV) monotherapy is
probably the most frequently used option for chronic hepatitis E
(11), and it also seems effective in severe acute infections (14, 15).
Research on HEV has long been hampered by a lack of effi-
cient cell culture models; however, in vitro cultures have been
established in recent years (16, 17). By employing a replicon, an
infectious virus yield assay, and immunofluorescence staining,
we investigated the antiviral activities of both IFN- and RBV
against in vitroHEV replication. Depletion of intracellular GTP
pools was found to be an important aspect of the mechanism of
action of RBV.
MATERIALS AND METHODS
In vitro transcription and capping. HEV Kernow-C1 p6 (GenBank ac-
cession number JQ679013) and p6/luc-encoding RNAs were transcribed
in vitro fromMluI-digested plasmidDNA (17) by use of the T7 RiboMAX
Large Scale RNA production system (Promega, Madison, WI) and were
capped with the ScriptCap m7G capping system (Cellscript, Madison,
WI). To generate a transfection control for luminescence-based antiviral
assays, the T7-IRES-FFLuc-YFsfRNA DNA fragment was PCR amplified
from pT7-IRES-FFLuc-YFsfRNA with primers 5=-CATATGTCGACTAA
TACGACTCACTATAGGGATCCGCCCCTCTCCC-3= and 5=-AGTGG
TTTTGTGTTTGTCATCC-3= and with Kapa HiFi HotStart ReadyMix
mastermix (Kapa Biosystems,Woburn,MA). The resulting fragment was
in vitro transcribed. The internal ribosome entry site (IRES) alleviates the
need for capping, and the yellow fever virus-derived small flaviviral RNA
(YFsfRNA) enhances the cellular stability of this firefly luciferase (FFLuc)-
encodingRNA (18). The generation of pT7-IRES-FFLuc-YFsfRNAwill be
described elsewhere.
Cells and viruses. Huh7 cells (a kind gift from Ralf Bartenschlager,
University of Heidelberg, Heidelberg, Germany) and HepG2/C3A cells (a
kind gift from Luc Verschaeve, Scientific Institute of Public Health, Brus-
sels, Belgium) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco, Carlsbad, CA) supplemented with 10% fetal bovine se-
rum (FBS; Integro, Leuvenheim, Netherlands) in a humidified 5% CO2
incubator at 37°C.
To obtain infectious HEV stocks, HepG2/C3A cells seeded in a 6-well
plate (BD Falcon, Franklin Lakes, NJ) were transfected with capped Ker-
now-C1 p6RNAby use ofDMRIE-C (Invitrogen, Carlsbad, CA) andwere
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incubated at 35°C. Part of the culture medium was changed every 2 to 3
days to ensure long-term cell survival, and culture mediumwas harvested
from the original plate after 34 days of incubation. The obtained virus
stock was propagated oncemore in HepG2/C3A cells, with weekly chang-
ing of half of the culturemedium. Culturemediumwas harvested after 22
days. Since the Kernow-C1 p6 strain has been adapted to growth in
HepG2/C3A cells (19), culturing of HEV p6 virus stocks in these cells
resulted in higher-titer stocks than those obtained by culture inHuh7 cells
(results not shown).
HEV strain Sar 55 (GenBank accession number M80581), Akluj (ac-
cession number AF107909), LBPR-0379 (accession number JN564006),
and Kernow-C1 (accession number HQ389543) inocula were obtained
from human stool samples, while the human Mex 14 strain (accession
numberM74506) was passaged once in a rhesus macaque. The work with
human isolates was carried out under approved protocols of the Carolinas
Medical Center (IRB-10-0709B) and the Royal Cornwall Hospital Trust
(IRB-06Q2101/61), with the informed consent of the patients. The hous-
ing, maintenance, and care of the rhesus macaque met or exceeded all
requirements for primate husbandry as specified in theGuide for the Care
and Use of Laboratory Animals (20).
Compounds. IFN- 2a (Roferon-A)was purchased fromRoche Phar-
maceuticals (Basel, Switzerland), diluted to 3  105 international units
(IU)/ml in phosphate-buffered saline (PBS; Lonza, Basel, Switzerland)
supplemented with 10% glycerol and 0.1% bovine serum albumin, stored
at 80°C, and kept at 4°C after thawing. RBV [1-(-D-ribofuranosyl)-
1H-1,2,4-triazole-3-carboxamide (Virazole)] was purchased from ICN
Pharmaceuticals (Costa Mesa, CA). 5-Ethynyl-1--D-ribofuranosylimi-
dazole-4-carboxamide (EICAR) was a gift from Akira Matsuda (Hok-
kaido University), and mycophenolic acid (MPA) was purchased from
Santa Cruz Biotechnology (Dallas, TX). Guanosine was from Sigma-
Aldrich (St. Louis, MO). Stock solutions of the compounds were made in
dimethyl sulfoxide (DMSO) and stored at 4°C.
Luminescence-based antiviral assay. Huh7 cells were seeded in 96-
well plates (BD Falcon) at 7.5 103 cells per well in 100l of DMEMwith
10% FBS and were incubated at 37°C. After 24 h, cell layers were washed
once with DMEM and transfected with IRES-FFLuc-YFsfRNA and capped
p6/luc RNA (100 ng per well [each]) by use of DMRIE-C reagent (0.2l per
well) according to the manufacturer’s instructions. For cell control (CC)
wells, viral RNA was omitted. Plates were incubated at 37°C for 4 h. After-
wards, the transfection medium was removed, cell layers were washed twice
with PBS (100l per well), and 100l of compound diluted in DMEMwith
10% FBS was added to each well. For virus control (VC) and CC wells, the
compound was omitted. After incubation at 35°C for 3 days, 20 l of the
culturemediumwas transferred to awhite 96-wellCulturPlate (PerkinElmer,
Waltham,MA), and luminescence produced by the secretedGaussia lucifer-
ase (GLuc) was determined after addition of 50 l of diluted Renilla lu-
ciferase assay substrate (Promega). A pilot study indicated that incubation
for 3 dayswas sufficient to obtain a 100-fold increase inGaussia-generated
luminescence (data not shown), allowing for a fast and relatively sensitive
readout. The remaining culture medium was removed, and 20 l of pas-
sive lysis buffer (Promega) was added to each well. Next, the buffer with
lysed cells was transferred to awhite 96-well CulturPlate containing 100l
of diluted FFLuc assay substrate (Promega) per well, and luminescence
counts were obtained. GLuc luminescence values were normalized with
the following formula: LucNormcompound  (GLucrepliconcompound 
GlucCC)/FFLucrepliconcompound. The percent antiviral activity was calcu-
lated as 100 (LucNormcompound/LucNormVC 100). The 50%effective
concentration (EC50) was defined as the concentration of compound that
caused a 50% reduction in the LucNorm signal compared to that of VC
and was calculated through logarithmic interpolation. For toxicity evalu-
ation, plates were prepared in parallel with antiviral assay mixtures, but
the transfection step was omitted. After incubation for 3 days at 35°C,
medium was removed and replaced with 100 l of a 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium/phenazinemethosulfate (MTS/PMS; Promega) solution,
as described previously (21). After an incubation period of 2 h at 37°C,
the optical density (OD) at 498 nm was determined for each well. The
percent cell viability was calculated as follows: % viabilityODcompound/
ODCC 100.
For combination studies, a checkerboard with 3-fold dilutions of RBV
and 4-fold dilutions of IFN- was used. Data were analyzed with the
MacSynergy II template at the 95%confidence level (22).Volumesof synergy
or antagonism below 25 M2% are considered insignificant, while values
between25and50M2%areminorbut significant.Volumesbetween50and
100M2% indicate moderate synergy or antagonism (22–24).
Infectious virus yield assay.Huh7 cells were seeded in 6-well plates at
5  105 cells per well in 2 ml of DMEM with 10% FBS, penicillin (100
units/ml; Gibco), streptomycin (100 g/ml; Gibco), and amphotericin B
(Fungizone) (2.5 g/ml; Gibco) and were incubated at 37°C. After 24 h,
culture medium was removed and cell layers were inoculated with infec-
tious p6 virus at 2.1 105 RNA copies/ml in 1ml of mediumwith DMSO
(0.5%) or compound and then incubated at 35°C. After 5 h, the inoculum
was removed, cell layers were washed 3 times with 2ml of PBS, and 3ml of
medium with DMSO or compound was added to each well. After 1 h, a
150-l sample was taken and stored at80°C. Since HEV replication in
vitro is rather poor, regular changing of the culture medium was required
to allow cell survival over the full duration of the assay. Consequently, 750
l was removed from each well every 2 to 3 days and stored at80°C, and
1mlof freshmediumwithDMSOorcompoundwasadded.Theviral loads in
samples from 1 h, 12 or 13 days, and 20 days postinfection were determined
byreverse transcription-quantitativePCR(RT-qPCR). Statistical significance
was calculated with the Mann-Whitney U test. On day 20 postinfection, all
medium was removed from the plate, cell layers were washed with 2 ml of
PBS, and 1ml ofMTS/PMS solutionwas added for evaluation of compound
cytotoxicity. Cultures were incubated for 2 h at 37°C, and subsequently, the
OD at 498 nm was determined for 100 l from each well. Cell viability was
expressed as a percentage of the DMSO control level.
Immunofluorescence analysis and focus-formingassay.HEVstrains
Sar 55, Akluj, Mex 14, LBPR-0379, Kernow-C1, and Kernow-C1 p6 were
inoculated ontoHepG2/C3A cells seeded in 8-well Lab-Tek II CC2 cham-
ber slides (Nunc, Penfield, NY). Cells in triplicate wells were incubated
with medium with or without RBV at 200 M. After 3 days, cells were
fixed and stained for capsid protein as described before (19). Each well was
manually scanned, and fluorescent cells or foci were counted. Cell viability of
HepG2/C3Acells treatedwithRBVat200Mfor3dayswasassessedwith the
MTS/PMS method. RBV was used at a higher concentration than that in
Huh7 cells because HepG2 cells appear to require higher concentrations to
induce intracellular GTP depletion (e.g., see reference 25).
Quantification of intracellular GTP concentrations. RBV, MPA, or
EICARwas added to 1-day-old cultures ofHuh7 cells inDMEMwith 10%
FBS in 25-cm2 flasks. For RBV, concentrations of 2.5, 10, 25, and 100M
were tested. For MPA and EICAR, concentrations of 0.1, 0.25, 1, and 2.5
M were used. Untreated CC cultures were included as well. Flasks were
incubated at 35°C for 3 days, and subsequently, cells were detached using
trypsin-EDTA solution (Gibco) and collected by centrifugation. Nucleo-
tides were extracted from the cell pellet, andGTP levels were quantified by
high-performance liquid chromatography as described previously (26).
The 50% inhibitory concentration (IC50) was defined as the concentra-
tion of compound required to reduce theGTP levels to 50%of the levels in
untreated control cultures.
RT-qPCR. Viral RNA was extracted from culture medium by use of a
NucleoSpinRNAvirus kit (Macherey-Nagel,Düren,Germany) according
to the manufacturer’s instructions. Primer and probe sequences for
TaqMan-based quantification of HEV RNA were published previously
(27). The forward primer 5=-GGTGGTTTCTGGGGTGAC-3= and the re-
verse primer 5=-AGGGGTTGGTTGGATGAA-3= were used. The probe
was labeled with 6-carboxyfluorescein (FAM) at the 5= end and with a
minor groove binder (MGB) at the 3= end (5=-FAM-TGATTCTCAGCC
CTTCGC-MGBNFQ-3=) (28). Reactions were performed with One-Step
qRT-PCR mix (Eurogentec, Seraing, Belgium) in a final volume of 25 l
Debing et al.
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containing 250 nM of each primer, 100 nM of probe, and 5 l of RNA
sample. PCR was performed using an ABI 7500 Fast real-time PCR
system (Applied Biosystems, Foster City, CA) under the following
conditions: 30 min at 48°C and 10min at 95°C, followed by 40 cycles of
15 s at 95°C and 1 min at 60°C. Data were analyzed with ABI Prism
7500 SDS software (version 1.3.1; Applied Biosystems). For absolute
quantification, standard curves were generated using 10-fold dilutions
of the cloned target cDNA.
RESULTS
We used a transient GLuc-expressing genotype 3 replicon (Ker-
now-C1 p6/luc) (17) in Huh7 hepatoma cells to assess the poten-
tial anti-HEV activity of RBV and IFN-, two drugs whose clinical
efficacy has been reported in several case studies of HEV-infected
patients (11, 13). Both RBV and IFN- efficiently inhibited HEV
replication, with EC50s of 3	 2 M (0.7	 0.5 g/ml) and 1.3	
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FIG 1 Inhibitory activities of IFN- andRBVagainstHEV replication.Huh7 cells were transfectedwith cappedp6/lucRNAand treatedwithRBV (A) or IFN- (B) for
3 days. (C) Antiviral activities below or above those expected for RBV–IFN- combinations. (D) Antiviral activities were also assessed in an infectious virus yield assay
with RT-qPCR detection of viral RNA. *, P
 0.05; **, P
 0.01. GE, genome equivalents. (E) RBV (200M) inhibited formation of foci in HepG2/C3A cells infected
with strains Sar 55, Akluj,Mex 14, LBPR-0379,Kernow-C1, andKernow-C1p6. (F)Cell viability ofHuh7 cells used in the infectious virus yield assay after 20 days in the
presence of IFN- or ribavirin, as assessed by theMTS/PMSmethod. (G) Cell viability of HepG2/C3A cells treated with RBV at 200M for 3 days was assessed by the
samemethod. Values represent means	 standard deviations (SD) for at least 3 independent experiments (A to D, F, and G) or 3 replicates (E).
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0.5 IU/ml, respectively (Fig. 1A and B). The combination of both
inhibitors resulted in amoderately synergistic antiviral effect, with
a synergy volume of 72 M2% (Fig. 1C). The combined antiviral
activity was maximally 22% above the expected value (at about 4
IU/ml IFN- and 0.4 M RBV).
Next, the potential antiviral activity was assessed in Huh7 cells
infected with the Kernow-C1 p6 virus (17). Viral replication was
quantified by means of RT-qPCR detection of viral RNA in the
culture medium. Both IFN- and RBV resulted in significant re-
ductions of viral titers at 12 and 20 days postinfection (Fig. 1D),
without decreasing cell viability (RBV concentrations of up to 100
M for 20 days) (Fig. 1F). A dose-dependent inhibition of viral
replication was observed with RBV, with a 4.1-log10 reduction in
viral titer after 20 days at a concentration of 100M. Some differ-
ences in the antiviral potency of RBV observed between the repli-
con and virus yield assays, though limited, may be explained by
the different setups (luminescence versus quantification of re-
leased viral RNA) and the respective time windows (3 versus 20
days) of the assays.
SinceRBVwas reported to be effective in the treatment of acute
genotype 1 infections (14, 15), the antiviral activity of RBV against
genotypes 1 and 2 was assessed. To this end, HepG2/C3A cells
were infected with wild-type isolate Sar 55, Akluj (both genotype
1), or Mex 14 (genotype 2) and stained for capsid protein. These
strains do not spread in cell culture but are able to replicate intra-
cellularly. RBV treatment (200 M) reduced the number of fluo-
rescent foci to almost zero (Fig. 1E). Comparable results were
obtained for thewild-type genotype 3 strains LBPR-0379 andKer-
now-C1 and for the cell culture-adaptedKernow-C1 p6 strain. No
cytotoxicity was observed for RBV at 200M for 3 days (Fig. 1G).
In addition, treatment of Sar 55 Gluc-containing replicon cells
with RBV resulted in a pronounced reduction of viral replication,
even when addition of RBVwas delayed until 4 days posttransfec-
tion and activity was assessed at 15 days posttransfection (data not
shown).
One of the proposedmechanisms of action for the broad-spec-
trum antiviral activity of RBV is that inhibition of IMP dehydro-
genase (IMPDH) by RBV 5=-monophosphate results in depletion
of the intracellular GTP pools, thus impeding RNA virus replica-
tion (29, 30). To determine whether GTP depletion is involved in
inhibition of in vitro HEV replication, we assessed the antiviral
activities of two known IMPDH inhibitors: MPA (an immuno-
suppressive agent) and EICAR, a 5-ethynylimidazole analogue of
RBV (31, 32).Marked inhibition ofHEV replicationwas observed
in the replicon assay, with EC50s of 0.20	 0.04 M and 0.115	
0.007 M for MPA and EICAR, respectively (Fig. 2A and B).
It has been shown for several viruses that are sensitive to RBV
that replenishing of intracellular GTP pools through addition of
exogenous guanosine restores virus replication (29, 33). Concor-
dantly, the anti-HEV activities of RBV, MPA, and EICAR were
reversed following addition of guanosine to the cell culture me-
dium (Fig. 3A to C). Next, we quantified the intracellular GTP
pools of Huh7 cells and the effects of different concentrations of
the three compounds. Normal GTP concentrations were calcu-
lated to be around 350M, andRBV,MPA, andEICAR effectively
depleted GTP pools, with IC50s of 18	 9 M, 0.5	 0.1 M, and
0.3	 0.2M, respectively. A strong correlation between both the
IC50s for GTP depletion and the respective antiviral EC50s was
calculated (R2 0.9998) (Fig. 3D).
DISCUSSION
Pegylated IFN- and RBV are the only drugs that are currently
available to treat acute and chronic hepatitis E (5, 7, 9). Treatment
duration is at least 12 weeks for chronic infections (13) and a
minimum of 3 weeks for acute infections (14, 15, 34) (compare
with the current standard of care for hepatitis C, i.e., pegylated
IFN- plus RBV for up to 48 weeks, combined with a protease
inhibitor for genotype 1 infections [35]). The scientific evidence
for these hepatitis E treatments is limited to a number of case series
and the in vitro activity against CTV, a HEV surrogate (36). None
of these interventions or the superiority of one over the other has
been validated in controlled trials yet. Here we demonstrate the
antiviral activity of IFN- and RBV against HEV in vitro, thus
providing additional evidence for the clinical use of these drugs. In
addition, a moderate but statistically significant synergy was cal-
culated for the combination of IFN- and RBV (Fig. 1C). The
clinical relevance of this observation is unclear, however, since
antiviral activity was maximally 22% above that expected. Never-
theless, since no antagonistic effects were observed, it might be an
option to treat patients with a combination of IFN- and RBV, as
is the case in the management of infections with hepatitis C virus
(HCV). Lower doses of both drugs may possibly be sufficient in a
combination regimen, thus reducing the frequency and severity of
adverse effects. In fact, successful combination therapy has already
been reported for a chronically HEV-infected HIV patient (37).
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When the in vitro inhibitory concentrations of IFN- and RBV
are compared to the serum concentrations typically obtained in
(HCV-infected) patients, they seem to be in a roughly similar
concentration range. For instance, mean pegylated IFN- serum
concentrations of around 80 IU/ml have been reported (38),
which is considerably higher than the EC50 for inhibition of the
HEV replicon, although this is lower than the 300 IU/ml that
resulted in a 0.9-log10 reduction in the virus yield assay. For RBV,
serum concentrations between 8 and 13 M have been reported
(38, 39), and hepatic accumulation of ribavirin has been claimed,
with a steady-state liver concentration of 250 M (40). We calcu-
lated an EC50 of 3 M for RBV and observed strong antiviral
effects in the virus yield assays for concentrations above 10 M.
Although the relevance of such comparisonsmay be questionable,
the fact that both IFN- andRBVare active in vitro is in agreement
with the observed clinical efficacy of both in chronically HEV-
infected patients.
In a recent study by Dong and colleagues, the HEVORF3 pro-
tein was shown to inhibit IFN- signaling (41). In line with this
finding, high concentrations of IFN- were required to reduce
release of HEV RNA into the culture medium after infection (e.g.,
50% reduction at concentrations as high as 1,000 units/ml). A
similarly high concentration of 300 IU/ml was needed in our in-
fectious HEV system to achieve reductions of viral RNA levels in
the virus yield assay of 98% and 87% at 12 and 20 days postinfec-
tion, respectively (Fig. 1D). In the replicon assay, on the other
hand, we observed strong inhibition by IFN- at concentrations
as low as 10 IU/ml (Fig. 1B). Slight differences obtained in the
infectious HEV system may be explained by the use of different
cell lines (A549 versus Huh7) and virus isolates and/or the fact
that the HEV infection was already established before the start of
IFN- treatment in the study of Dong et al., while IFN- was
included in the inoculumduring initial infection in our virus yield
system. However, the pronounced potency of IFN- against the
subgenomic HEV replicon system can readily be explained by the
lack of an interferon-antagonizing activity in p6/luc, where ex-
pression of ORF3 is ablated by replacement with a reporter cas-
sette, making the replicon especially susceptible to inhibition by
IFN-. This is fully in line with the findings of Dong et al. (41).
The data presented here indicate that depletion of cellular GTP
pools is the predominant mechanism by which ribavirin inhibits
in vitro HEV replication. It is unclear, however, to what extent
hepatic GTP levels can be decreased by RBV in vivo (30). Other
proposed mechanisms of action of RBV include immunomodu-
latory effects, modulation of IFN-stimulated gene expression, le-
thalmutagenesis forcing the virus into an error catastrophe, inter-
ference with viral methyltransferase activity, direct inhibition of
the viral polymerase, and inhibition of eukaryotic initiation factor
0.01 0.1 1 10 100
0
20
40
60
80
100
0
20
40
60
80
100
RBV (µM)
%
an
tiv
ira
la
ct
iv
ity
%
ce
ll
vi
ab
ili
ty
0.001 0.01 0.1 1 10
0
20
40
60
80
100
0
20
40
60
80
100
MPA (µM)
%
an
tiv
ira
la
ct
iv
ity
%
ce
ll
vi
ab
ili
ty
0.01 0.1 1 10
0
20
40
60
80
100
0
20
40
60
80
100
EICAR (µM)
%
an
tiv
ira
la
ct
iv
ity
%
ce
ll
vi
ab
ili
ty
A
C
0.01 0.1 1 10
0.1
1
10
100
EC50 for inhibition of virus replication (µM)
IC
50
fo
rG
TP
de
pl
et
io
n
(µ
M
)
RBV
MPA
EICAR
R² = 0.9998
D
B
FIG 3 Replenishing GTP pools salvages HEV replication. Addition of exogenous guanosine to the culture medium (40 M) salvages HEV replication and
abolishes the antiviral effects of RBV (A), MPA (B), and EICAR (C) in the replicon assay. (D) Relationship between the IC50s for GTP depletion and EC50s for
inhibition of viral replication. Values represent means	 SD for at least 3 independent experiments.
Ribavirin Inhibits HEV Replication In Vitro
January 2014 Volume 58 Number 1 aac.asm.org 271
 o
n
 D
ecem
ber 22, 2013 by KU LEUVEN
http://aac.asm
.org/
D
ow
nloaded from
 
4E interfering with cap-dependent translation (30). Although one
or several of these mechanisms could be involved in the antiviral
activity of RBV against HEV, the results presented here suggest
that GTP depletion is an importantmechanism contributing to its
antiviral activity.
Interestingly, the use of mycophenolate mofetil, a prodrug of
MPA, for immunosuppressive therapy in transplant patients with
chronic hepatitis E was significantly associated with HEV clear-
ance (42). This observation is in accordance with the strong anti-
viral activity observed in our replicon assay (Fig. 2A). However, it
is questionable whether the antiviral effect outweighs the immu-
nosuppression that initially allowed HEV to establish a chronic
infection.
The replicon-based antiviral assay as described here is rather
labor-intensive, but to our knowledge, it is the first reported sys-
tem that allows testing of potential antiviral molecules targeting
HEV replication. In addition, the results of the infectious virus
yield indicate that it is feasible to study the impact of potential
antiviral compounds on the replication of full-length replication-
competent HEV. Although the isolation of the Kernow-C1 p6
strain was a major step forward, the replication kinetics are (still)
rather slow, thus requiring long incubation times to obtain suffi-
ciently high HEV titers for detection by RT-qPCR. Further adap-
tation to cell culture may be a possible solution; this strategy
proved successful, for instance, for hepatitis A virus and allowed
for the development of relatively fast virus yield assays (43).
In conclusion, the observed in vitro antiviral activities provide
additional support for the clinical use of both RBV and (pegy-
lated) IFN- for the treatment of severe cases of hepatitis E. How-
ever, both therapies require long treatment periods and can have
severe adverse effects. RBV dose reductions because of anemia
have resulted in treatment failure and death in some cases (15).
Consequently, the assays presented here may serve as a starting
point for developing convenient systems for high-throughput
screening. This should allow the development of more potent
anti-HEV drugs with a better safety profile. Ideally, these drugs
should be safe during pregnancy. Since HEV appears to be emerg-
ing and its impact on public health has been underestimated, it
would be wise to invest in research toward such antivirals.
ACKNOWLEDGMENTS
We thank Ralf Bartenschlager (University of Heidelberg, Germany) for
Huh7 cells, Luc Verschaeve (Scientific Institute of PublicHealth, Brussels,
Belgium) for HepG2/C3A cells, and Akira Matsuda (Hokkaido Univer-
sity, Japan) for providing EICAR. We are grateful to Hendrik Thibaut,
Pieter Leyssen, Jan Paeshuyse, and Suzanne Kaptein for helpful discus-
sions and to Ria Van Berwaer for excellent technical assistance.
Y.D. is a fellow of the Research Foundation-Flanders (FWO). Q.P. is
supported by a Sheila Sherlock Fellowship from the EuropeanAssociation
for the Study of the Liver (EASL). This work was supported by KULeuven
Geconcerteerde Onderzoeksacties (GOA/10/014) and by EU FP7 project
SILVER (260644) and in part by the Intramural Research Program of the
National Institutes of Health, National Institute of Allergy and Infectious
Diseases (S.U.E.).
REFERENCES
1. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J,
Dalton HR. 2012. Hepatitis E. Lancet 379:2477–2488. http://dx.doi.org
/10.1016/S0140-6736(11)61849-7.
2. Aggarwal R, Jameel S. 2011. Hepatitis E. Hepatology 54:2218–2226. http:
//dx.doi.org/10.1002/hep.24674.
3. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. 2012. The
global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology
55:988–997. http://dx.doi.org/10.1002/hep.25505.
4. Haqshenas G, Shivaprasad HL, Woolcock PR, Read DH, Meng XJ.
2001. Genetic identification and characterization of a novel virus related
to human hepatitis E virus from chickens with hepatitis-splenomegaly
syndrome in the United States. J. Gen. Virol. 82:2449–2462.
5. Johne R, Heckel G, Plenge-Bönig A, Kindler E, Maresch C, Reetz J,
Schielke A, Ulrich RG. 2010. Novel hepatitis E virus genotype in Norway
rats, Germany. Emerg. Infect. Dis. 16:1452–1455. http://dx.doi.org/10
.3201/eid1609.100444.
6. Zhao C, Ma Z, Harrison TJ, Feng R, Zhang C, Qiao Z, Fan J, Ma H, Li
M, Song A,Wang Y. 2009. A novel genotype of hepatitis E virus prevalent
among farmed rabbits in China. J. Med. Virol. 81:1371–1379. http://dx
.doi.org/10.1002/jmv.21536.
7. Raj VS, Smits SL, Pas SD, Provacia LBV, Moorman-Roest H, Osterhaus
ADME, Haagmans BL. 2012. Novel hepatitis E virus in ferrets, the Neth-
erlands. Emerg. Infect. Dis. 18:1369–1370. http://dx.doi.org/10.3201
/eid1808.111659.
8. Drexler JF, Seelen A, Corman VM, Fumie Tateno A, Cottontail V,
Melim Zerbinati R, Gloza-Rausch F, Klose SM, Adu-Sarkodie Y, Op-
pong SK, Kalko EKV, Osterman A, Rasche A, Adam A, Müller MA,
Ulrich RG, Leroy EM, Lukashev AN, Drosten C. 2012. Bats worldwide
carry hepatitis E virus-related viruses that form a putative novel genus
within the family Hepeviridae. J. Virol. 86:9134–9147. http://dx.doi.org
/10.1128/JVI.00800-12.
9. Batts W, Yun S, Hedrick R, Winton J. 2011. A novel member of the
family Hepeviridae from cutthroat trout (Oncorhynchus clarkii). Virus
Res. 158:116–123. http://dx.doi.org/10.1016/j.virusres.2011.03.019.
10. Teshale EH, Hu DJ, Holmberg SD. 2010. The two faces of hepatitis E
virus. Clin. Infect. Dis. 51:328–334. http://dx.doi.org/10.1086/653943.
11. Debing Y, Jochmans D, Neyts J. 2013. Intervention strategies for emerg-
ing viruses: use of antivirals. Curr. Opin. Virol. 3:217–224. http://dx.doi
.org/10.1016/j.coviro.2013.03.001.
12. Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C,
Dumortier J, Cannesson A, Cassuto-Viguier E, Thervet E, Conti F,
Lebray P, Dalton HR, Santella R, Kanaan N, Essig M, Mousson C,
Radenne S, Roque-Afonso AM, Izopet J, Rostaing L. 2011. Factors
associated with chronic hepatitis in patients with hepatitis E virus infec-
tion who have received solid organ transplants. Gastroenterology 140:
1481–1489. http://dx.doi.org/10.1053/j.gastro.2011.02.050.
13. Kamar N, Rostaing L, Izopet J. 2013. Hepatitis E virus infection in
immunosuppressed patients: natural history and therapy. Semin. Liver
Dis. 33:62–70. http://dx.doi.org/10.1055/s-0033-1338115.
14. Gerolami R, Borentain P, Raissouni F, Motte A, Solas C, Colson P.
2011. Treatment of severe acute hepatitis E by ribavirin. J. Clin. Virol.
52:60–62. http://dx.doi.org/10.1016/j.jcv.2011.06.004.
15. Pischke S, Hardtke S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann
W, Bara CL, Gottlieb J, Wenzel J, Manns MP, Wedemeyer H. 2013.
Ribavirin treatment of acute and chronic hepatitis E: a single-centre expe-
rience. Liver Int. 33:722–726. http://dx.doi.org/10.1111/liv.12114.
16. Okamoto H. 2013. Culture systems for hepatitis E virus. J. Gastroenterol.
48:147–158. http://dx.doi.org/10.1007/s00535-012-0682-0.
17. Shukla P, Nguyen HT, Faulk K, Mather K, Torian U, Engle RE,
Emerson SU. 2012. Adaptation of a genotype 3 hepatitis E virus to effi-
cient growth in cell culture depends on an inserted human gene segment
acquired by recombination. J. Virol. 86:5697–5707. http://dx.doi.org/10
.1128/JVI.00146-12.
18. Moon SL, Anderson JR, Kumagai Y, Wilusz CJ, Akira S, Khromykh AA,
Wilusz J. 2012. A noncoding RNA produced by arthropod-borne flavivi-
ruses inhibits the cellular exoribonuclease XRN1 and alters host mRNA
stability. RNA 18:2029–2040. http://dx.doi.org/10.1261/rna.034330.112.
19. Shukla P, Nguyen HT, Torian U, Engle RE, Faulk K, Dalton HR,
Bendall RP, Keane FE, Purcell RH, Emerson SU. 2011. Cross-species
infections of cultured cells by hepatitis E virus and discovery of an infec-
tious virus-host recombinant. Proc. Natl. Acad. Sci. U. S. A. 108:2438–
2443. http://dx.doi.org/10.1073/pnas.1018878108.
20. National Research Council. 2011. Guide for the care and use of laboratory
animals, 8th ed. National Academies Press, Washington, DC.
21. Jochmans D, Leyssen P, Neyts J. 2012. A novel method for high-
throughput screening to quantify antiviral activity against viruses that
induce limited CPE. J. Virol. Methods 183:176–179. http://dx.doi.org/10
.1016/j.jviromet.2012.04.011.
22. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to ana-
Debing et al.
272 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 D
ecem
ber 22, 2013 by KU LEUVEN
http://aac.asm
.org/
D
ow
nloaded from
 
lyze drug-drug interactions. Antiviral Res. 14:181–205. http://dx.doi.org
/10.1016/0166-3542(90)90001-N.
23. Delaney WE, 4th, Yang H, Miller MD, Gibbs CS, Xiong S. 2004.
Combinations of adefovir with nucleoside analogs produce additive anti-
viral effects against hepatitis B virus in vitro. Antimicrob. Agents Che-
mother. 48:3702–3710. http://dx.doi.org/10.1128/AAC.48.10.3702-3710
.2004.
24. Thibaut HJ, Leyssen P, Puerstinger G, Muigg A, Neyts J, De Palma AM.
2011. Towards the design of combination therapy for the treatment of
enterovirus infections. Antiviral Res. 90:213–217. http://dx.doi.org/10
.1016/j.antiviral.2011.03.187.
25. Suzuki A, Miyawaki Y, Okuyama E, Murata M, Ando Y, Kato I, Takagi
Y, Takagi A, Murate T, Saito H, Kojima T. 2013. Ribavirin-induced
intracellular GTP depletion activates transcription elongation in coagula-
tion factor VII gene expression. Biochem. J. 449:231–239. http://dx.doi
.org/10.1042/BJ20121286.
26. Balzarini J, Gago F, Kulik W, van Kuilenburg AB, Karlsson A, Peterson
MA, RobinsMJ. 2012. Introduction of a fluorine atom at C3 of 3-deazau-
ridine shifts its antimetabolic activity from inhibition ofCTP synthetase to
inhibition of orotidylate decarboxylase, an early event in the de novo py-
rimidine nucleotide biosynthesis pathway. J. Biol. Chem. 287:30444–
30454. http://dx.doi.org/10.1074/jbc.M112.378091.
27. Jothikumar N, Cromeans TL, Robertson BH, Meng XJ, Hill VR. 2006.
A broadly reactive one-step real-time RT-PCR assay for rapid and sensi-
tive detection of hepatitis E virus. J. Virol. Methods 131:65–71. http://dx
.doi.org/10.1016/j.jviromet.2005.07.004.
28. Garson JA, Ferns RB, Grant PR, Ijaz S, Nastouli E, Szypulska R, Tedder RS.
2012. Minor groove binder modification of widely used TaqMan probe for
hepatitis E virus reduces risk of false negative real-time PCR results. J. Virol.
Methods 186:157–160. http://dx.doi.org/10.1016/j.jviromet.2012.07.027.
29. Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The predominant
mechanism by which ribavirin exerts its antiviral activity in vitro against
flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehy-
drogenase. J. Virol. 79:1943–1947. http://dx.doi.org/10.1128/JVI.79.3
.1943-1947.2005.
30. Paeshuyse J, Dallmeier K, Neyts J. 2011. Ribavirin for the treatment of
chronic hepatitis C virus infection: a review of the proposed mechanisms
of action. Curr. Opin. Virol. 1:590–598. http://dx.doi.org/10.1016/j
.coviro.2011.10.030.
31. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron
PR, Murcko MA, Wilson KP. 1996. Structure and mechanism of inosine
monophosphate dehydrogenase in complexwith the immunosuppressant
mycophenolic acid. Cell 85:921–930. http://dx.doi.org/10.1016/S0092
-8674(00)81275-1.
32. Balzarini J, Karlsson A, Wang L, Bohman C, Horská K, Votruba I,
Fridland A, Van Aerschot A, Herdewijn P, De Clercq E. 1993. Eicar
(5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel
potent inhibitor of inosinate dehydrogenase activity and guanylate bio-
synthesis. J. Biol. Chem. 268:24591–24598.
33. Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R.
2006. Inhibition of dengue virus replication by mycophenolic acid and
ribavirin. J. Gen. Virol. 87:1947–1952. http://dx.doi.org/10.1099/vir.0
.81655-0.
34. Goyal R, Kumar A, Panda SK, Paul SB, Acharya SK. 2012. Ribavirin
therapy for hepatitis E virus-induced acute on chronic liver failure: a pre-
liminary report. Antivir. Ther. 17:1091–1096. http://dx.doi.org/10.3851
/IMP2317.
35. Liang TJ, Ghany MG. 2013. Current and future therapies for hepatitis C
virus infection. N. Engl. J.Med. 368:1907–1917. http://dx.doi.org/10.1056
/NEJMra1213651.
36. Debing Y, Winton J, Neyts J, Dallmeier K. 2013. Cutthroat trout virus as
a surrogate in vitro infection model for testing inhibitors of hepatitis E
virus replication. Antiviral Res. 100:98–101. http://dx.doi.org/10.1016/j
.antiviral.2013.07.013.
37. Dalton HR, Keane FE, Bendall R, Mathew J, Ijaz S. 2011. Treatment of
chronic hepatitis E in a patient with HIV infection. Ann. Intern. Med. 155:
479–480. http://dx.doi.org/10.7326/0003-4819-155-7-201110040-00017.
38. Nicot F, Legrand-Abravanel F, Lafont T, Dubois M, Sauné K, Pasquier
C, Chatelut E, Izopet J. 2008. Serum concentrations of ribavirin and
pegylated interferon and viral responses in patients infected withHIV and
HCV. J. Med. Virol. 80:1523–1529. http://dx.doi.org/10.1002/jmv.21227.
39. Larrat S, Stanke-Labesque F, Plages A, Zarski J-P, Bessard G, Souvignet
C. 2003. Ribavirin quantification in combination treatment of chronic
hepatitis C. Antimicrob. Agents Chemother. 47:124–129. http://dx.doi
.org/10.1128/AAC.47.1.124-129.2003.
40. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R,
Cameron CE. 2000. The broad-spectrum antiviral ribonucleoside ribavi-
rin is anRNAvirusmutagen.Nat.Med. 6:1375–1379. http://dx.doi.org/10
.1038/82191.
41. Dong C, Zafrullah M, Mixson-Hayden T, Dai X, Liang J, Meng J,
Kamili S. 2012. Suppression of interferon- signaling by hepatitis E virus.
Hepatology 55:1324–1332. http://dx.doi.org/10.1002/hep.25530.
42. Pischke S, Stiefel P, Franz B, Bremer B, Suneetha PV, Heim A, Ganzen-
mueller T, Schlue J, Horn-Wichmann R, Raupach R, Darnedde M, Scheib-
ner Y, Taubert R, Haverich A, Manns MP, Wedemeyer H, Bara CL. 2012.
Chronic hepatitis E in heart transplant recipients. Am. J. Transplant. 12:
3128–3133. http://dx.doi.org/10.1111/j.1600-6143.2012.04200.x.
43. Debing Y, Kaplan GG, Neyts J, Jochmans D. 2013. Rapid and convenient
assays to assess potential inhibitory activity on in vitro hepatitis A replica-
tion. Antiviral Res. 98:325–331. http://dx.doi.org/10.1016/j.antiviral.2013
.03.016.
Ribavirin Inhibits HEV Replication In Vitro
January 2014 Volume 58 Number 1 aac.asm.org 273
 o
n
 D
ecem
ber 22, 2013 by KU LEUVEN
http://aac.asm
.org/
D
ow
nloaded from
 
